Albumin Market Size Projected to Reach $9.33 billion by 2034 | 6%

According to Straits Research, the global albumin market size was valued at $8.11 billion in 2025 and is projected to grow from $8.71 billion in 2026 to $15.46 billion by 2034, registering a CAGR of 7.43% during the forecast period 2026–2034.

The global albumin market is experiencing consistent expansion, driven by its extensive uses in the pharmaceutical, clinical diagnostics, biotechnology, and life sciences industries.  Albumin, a hydrophilic protein sourced from human plasma or recombinant origins, is essential for sustaining oncotic pressure and facilitating the movement of critical chemicals such as hormones and fatty acids.  The extensive clinical application in critical care, therapy of hypoalbuminemia, and medication delivery perpetuates global demand.  The market is expanding, particularly in emerging economies with enhanced healthcare infrastructure and increased access to plasma-derived medicines.  The rising incidence of liver illness, nephrotic syndrome, and burns, along with an increase in surgical operations, is driving demand.

Market Dynamics

Advancements in plant-based biotechnology drive market growth

A primary catalyst for the albumin market is the advocacy for scalable, plant-based production techniques that diminish reliance on plasma-derived sources, especially in nations with substantial import dependence for essential biologics such as albumin.

• For example, in April 2025, Healthgen Biotechnology, a biotechnology company based in China, obtained regulatory approval from the National Medical Products Administration (NMPA) for its rice-derived recombinant human albumin injection.  The injectable, designed to address hypoalbuminemia, is manufactured via a patented plant-based platform that facilitates large-scale production; 25 kilos of rice may yield albumin equivalent to five litres of human plasma.

As nations such as China increase their investment in recombinant biologics, the demand for scalable, animal-free sources of albumin is anticipated to grow.

Nanogold-albumin conjugates in targeted oncology nanomedicine create tremendous opportunities

Incorporating albumin-based nanocarriers in precision oncology, especially via nanogold–albumin conjugate advancements, represents a burgeoning prospect.  Researchers are redefining albumin from a passive excipient to a crucial functional substance in advancing cancer treatments and next-generation nanomedicine platforms to enhance efficacy and safety.

• For instance, in March 2025, a significant review paper in Nanoscale examined groundbreaking advancements in this field, including nanosystems, such as supramolecular albumin-coated gold nanoparticles and albumin-templated ultra-small gold nanoclusters.  These conjugates are designed for optimal medication administration and diagnostic imaging.  Their adjustable surface chemistry, extended circulation time, and minimal immunogenicity render them optimal for delivering various therapeutic agents, including chemotherapeutics and nucleic acids, while facilitating real-time imaging.

With the growing clinical interest in albumin-functionalized nanocarriers, this breakthrough presents a significant opportunity for biotechnology corporations, diagnostic developers, and pharmaceutical companies to invest in albumin as a fundamental platform material.

Regional Analysis

North America dominates the global albumin market, bolstered by a strong biopharmaceutical sector and extensive clinical demand for albumin-based treatments.  The region significantly utilises albumin in hospital environments for volume resuscitation, shock management, and surgical assistance, particularly in trauma and critical care units.  Moreover, sophisticated research infrastructure and biotechnology innovation centres have broadened the use of albumin beyond its conventional uses.  The integration of this technology in drug delivery systems, plasma fractionation, and novel diagnostics signifies the region's transition towards high-value therapeutic solutions.  Regulatory clarity, robust reimbursement structures, and steady clinical adoption bolster North America's preeminence in the albumin sector.

Market Segments

1. By Product Type
   1. Human Serum Albumin (HSA)
   2. Recombinant Albumin
   3. Bovine Serum Albumin (BSA)
2. By Application
   1. Drug Delivery
   2. Vaccine Stabilisation
   3. Therapeutic Use (Liver Disease, Burns, Trauma)
   4. Diagnostic Applications
   5. Cell Culture Media and Biotechnology
3. By Distribution Channel
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Online Pharmacies
   4. Direct Sales (Manufacturers to Hospitals)
4. By End-User
   1. Hospitals
   2. Clinics
   3. Research and Academic Institutes
   4. Biopharmaceutical Companies
   5. Diagnostic Laboratories